Transthyretin-related hereditary amyloidosis
| Transthyretin-related hereditary amyloidosis | |
|---|---|
| Classification and external resources | |
| OMIM | 105210 |
| eMedicine | article/335301 |
Familial amyloid polyneuropathy (FAP), also called transthyretin-related hereditary amyloidosis, transthyretin amyloidosis or Corino de Andrade's disease,[1] is an autosomal dominant[2] neurodegenerative disease. It is a form of paramyloidosis, and was first identified and described by Portuguese neurologist Mário Corino da Costa Andrade, in the 1950s.[3] FAP can now be ameliorated by liver transplantation and/or Tafamidis (Vyndaqel) treatment, thus there is reason to be optomistic that these patients will live much longer than their untreated counterparts.
Contents |
[edit] Characteristics
Usually manifesting itself between 20 and 40 years of age, it is characterized by pain, paresthesia, muscular weakness and autonomic dysfunction. In its terminal state, the kidneys and the heart are affected. FAP is characterized by the systemic deposition of amyloidogenic variants of the transthyretin protein, especially in the peripheral nervous system, causing a progressive sensory and motorial polyneuropathy.
[edit] Cause and genetics
FAP is caused by a mutation of the TTR gene, located on human chromosome 18q12.1-11.2.[4] A replacement of valine by methionine at position 30 (TTR V30M) is the mutation most commonly found in FAP.[1] The variant TTR is mostly produced by the liver.[citation needed] The transthyretin protein is a tetramer. The tetramer has to dissociate into misfolded monomers to aggregate into a variety of structures including amyloid fibrils. Because most patients are heterozygotes, they deposit both mutant and wild type TTR subnits.
FAP is inherited in an autosomal dominant manner.[2] This means that the defective gene responsible for the disorder is located on an autosome (chromosome 18 is an autosome), and only one copy of the defective gene is sufficient to cause the disorder, when inherited from a parent who has the disorder.
[edit] Prognosis
In the absence of a liver transplant, FAP is invariably fatal, usually within a decade. The disadvatage of liver transplantation is approximately 10% of the subjects die from the procedure or complications resulting from the procedure, which is a form of gene therapy wherein the liver expressing wild type and mutant TTR is replaced by a liver only expressing wild type TTR. Moreover, transplanted patients must take immune suppresants (drugs) for the remainder of their life, which can lead to additional complications. In late 2011, the European Medicines Agency approved the transthyretin kinetic stabilizer Tafamidis or Vyndaqel discovered by Jeffery W. Kelly and developed by FoldRx pharmaceuticals (acquired by Pfizer) for the treatment of FAP based on clinical trial data. Tafamidis (20 mg once daily) slowed the progression of FAP over a 36 month period and importantly reversed the weight loss and muscle wasting associated with disease progression.
[edit] Epidemiology
This disease is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), with more than 1000 affected people, coming from about 500 families, where 70% of the people develop the illness. It was brought by Vikings from Scandinavia during the Middle Age. In northern Sweden, more specifically Piteå, Skellefteå and Umeå, 1.5% of the population has the mutated gene. There are many other populations in the world who exhibit the illness after having developed it independently.
[edit] Regulatory Agency Approved Treatments
The drug tafamidis[5] has completed a phase II/III 18 month long placebo controlled clinical trial[6] and these results in combination with an 18 month follow-on study demonstrated that Tafamidis or Vyndaqel slowed progression of FAP, particularly when administered to patients early in the course of FAP.[7] This drug is now approved by the European Medicines Agency and the drug will be submitted to the FDA for approval in the United States in 2012.
[edit] Animal models
Combined Doxycycline and TUDCA treatment (in human tolerable doses) significantly lowered fibrillar Transthyretin (TTR) amyloid deposition in transgenic TTR mouse models. The authors propose this treatment in FAP, particularly in the early stages of disease.[8]
[edit] See also
[edit] References
- ^ a b Online 'Mendelian Inheritance in Man' (OMIM) 105210
- ^ a b Ando, Y.; Ueda, M. (May 2008). "Novel methods for detecting amyloidogenic proteins in transthyretin related amyloidosis". Frontiers in bioscience : a journal and virtual library 13: 5548–5558. PMID 18508604.
- ^ Andrade C (September 1952). "A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves". Brain 75 (3): 408–27. PMID 12978172. http://brain.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12978172.
- ^ Online 'Mendelian Inheritance in Man' (OMIM) 176300
- ^ Tafamidis structure
- ^ in Patients With Familial Amyloidosis.
- ^ http://protomag.ticsnetwork.com/statics/MGH_SP10_Protein_fold_F2.pdf
- ^ Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ (Jul 2010). "Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models" (Free full text). Journal of Translational Medicine 8: 74. PMC 2922089. PMID 20673327. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2922089.
[edit] External links
- GeneReviews/NIH/NCBI/UW entry on Familial Transthyretin Amyloidosis
- Stanford University Amyloid Center
- Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D, Saraiva MJ (October 2001). "Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways". J. Neurosci. 21 (19): 7576–86. PMID 11567048. http://www.jneurosci.org/cgi/pmidlookup?view=long&pmid=11567048.
- Portuguese Paramyloidosis Association (in Portuguese)
- Center for study and support for Paramyloidosis (in Portuguese)
|
|||||||||||||||||||||||||
